Town & Country Bank & Trust CO dba First Bankers Trust CO boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 18,373 shares of the biopharmaceutical company’s stock after buying an additional 2,774 shares during the quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Gilead Sciences were worth $1,241,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of GILD. Geode Capital Management LLC grew its position in Gilead Sciences by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 16,867,065 shares of the biopharmaceutical company’s stock worth $1,053,332,000 after purchasing an additional 835,915 shares in the last quarter. Parnassus Investments CA grew its position in Gilead Sciences by 21.2% during the 1st quarter. Parnassus Investments CA now owns 13,074,555 shares of the biopharmaceutical company’s stock worth $849,976,000 after purchasing an additional 2,288,767 shares in the last quarter. Norges Bank purchased a new position in Gilead Sciences during the 4th quarter worth approximately $798,882,000. Sanders Capital LLC grew its position in Gilead Sciences by 5.0% during the 1st quarter. Sanders Capital LLC now owns 11,291,933 shares of the biopharmaceutical company’s stock worth $793,701,000 after purchasing an additional 539,793 shares in the last quarter. Finally, Legal & General Group Plc grew its position in Gilead Sciences by 6.7% during the 4th quarter. Legal & General Group Plc now owns 6,552,231 shares of the biopharmaceutical company’s stock worth $409,842,000 after purchasing an additional 408,910 shares in the last quarter. Hedge funds and other institutional investors own 78.66% of the company’s stock.

Several research firms have weighed in on GILD. Citigroup upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and set a $66.80 price objective on the stock in a research report on Wednesday, May 22nd. Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research report on Friday, April 26th. They set an “outperform” rating and a $82.00 price objective on the stock. Maxim Group set a $84.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, July 15th. Goldman Sachs Group set a $27.00 target price on shares of Melco Resorts & Entertainment and gave the company a “buy” rating in a research note on Tuesday, May 28th. Finally, Raymond James set a $60.00 target price on shares of Banner and gave the company a “buy” rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $81.09.

GILD stock opened at $66.92 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.53 and a current ratio of 3.62. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61. The firm has a fifty day simple moving average of $67.16. The firm has a market cap of $84.55 billion, a price-to-earnings ratio of 10.88, a PEG ratio of 4.01 and a beta of 1.12.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the business earned $1.48 EPS. Gilead Sciences’s quarterly revenue was up 3.8% compared to the same quarter last year. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.62 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.77%. The ex-dividend date was Thursday, June 13th. Gilead Sciences’s payout ratio is presently 40.98%.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total transaction of $399,850.00. Following the completion of the transaction, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total transaction of $468,504.00. Following the transaction, the executive vice president now directly owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,884 shares of company stock valued at $1,054,459. 0.20% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Percentage Decliners

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.